Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from AstraZeneca

Alex Jones promotes false conspiracy that monkeypox outbreak is due to Covid-19 vaccines

The monkeypox outbreak theory is just the latest unproven claim to be promoted by the anti-vaxer

The Independent UK

What happened to the AstraZeneca vaccine? Now rare in rich countries, it’s still saving lives around the world

The AstraZeneca vaccine, developed in partnership with the University of Oxford, was one of the first vaccines available for use in the UK and around the world during the COVID pandemic.

The Conversation

Heartbroken family of man take legal action after he died of blood clots two weeks after getting AstraZeneca jab

Jack Hurn had just bought his first home with his partner, and was planning on proposing to her

Wales Online

From analysis to the latest developments in health,
read the most diverse news in one place.

Ex-student, 31, died from blood clots in the brain two weeks after Covid jab

Jack Hurn from Redditch received first dose of AstraZeneca vaccine but died 11 days later in hospital from blood clots on his brain

Daily Mirror

From storage to transport, hurdles to getting COVID vaccine to N.Koreans

As North Korea battles its first known COVID outbreak, a lack of storage, chronic power shortages and inadequately trained medical staff pose acute challenges to inoculating its 25 million people - even with outside help, analysts said.

Reuters

AstraZeneca In-Licenses New Suite Of COVID-19 Antibody Candidate(s)

AstraZeneca plc (NASDAQ:AZN) moved to bolster its COVID-19 portfolio of antibodies with a $157 million licensing deal for experimental therapies developed by newly-launched UK-based biotech, RQ Biotechnology Ltd. In addition to the initial sum, AstraZeneca will pay possible royalty payments as part of the exclusive license to develop pre-clinical COVID antibodies engineered by RQ…

Benzinga

Robyn is one of 11 Australians who died after receiving the AstraZeneca vaccine. Her family speaks for the first time

Speaking publicly for the first time, her family say they fully support the COVID-19 vaccine rollout, but believe the government should have had a better plan to support families like theirs.

ABC News

Read news from The Economist, FT, and more,
with one subscription

Lung cancer patients to get new drug which can double life-expectancy

It means people with aggressive lung cancer can see their life expectancy go from two and half to five years

Wales Online

Biden co-hosting 2nd COVID summit as world's resolve falters

President Joe Biden will appeal for a renewed international commitment to attacking COVID-19 as the second global COVID-19 summit opens

The Independent UK

How Russia's war has hit Thailand, 11 weeks on

In recent months there have been positive signs that the world is returning to normal after the Covid-19 pandemic. People have worked tirelessly over the past two years to address and mitigate the consequences of the pandemic, spending billions on healthcare, vaccine development and deployment, social assistance payments, and other…

Bangkok Post

400 million COVID-19 vaccine doses dumped by Baltimore plant, congressional report finds

BALTIMORE — The Maryland-based vaccine maker Emergent BioSolutions was forced to destroy nearly 400 million doses of COVID-19 vaccine because of potential contamination at its East Baltimore plant, far more than previously known.

Tribune News Service

Sir John Bell: ‘Most people who have had the Covid vaccine are completely safe’

The renowned immunologist remains as upbeat about jabs – and UK life science – as he was in the depths of the pandemic

The Guardian - UK

The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

FDA Accepts AstraZeneca's sBLA for Imfinzi (durvalumab) in biliary tract cancer (BTC) with Priority Review

The U.S. Food and Drug Administration (FDA) has accepted AstraZeneca's (NASDAQ: AZN) supplemental Biologics License Application (sBLA) for Imfinzi (durvalumab), in combination with standard-of-care chemotherapy and granted Priority Review for patients with locally advanced or metastatic biliary tract cancer (BTC).

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

IBD 50 Stocks To Watch: Top Stock AstraZeneca Shows Continued Strength

AstraZeneca has become a household name thanks to its Covid-19 vaccine, though the company produces many other drugs to justify its $200 billion market cap.

The Guardian - UK

Pfizer accused of Covid profiteering as first-quarter sales hit $26bn

Pharma firm criticised over pricing and for keeping monopoly control over vaccine and new Paxlovid pill

The Independent UK

Families of people who died after taking Covid vaccine ‘ignored’ as zero compensation payouts made

More than 1,200 claims have been made to the government’s Vaccines Damages Payment Scheme, but no compensation has yet to be paid out

Benzinga

48 Stocks Moving In Friday's Mid-Day Session

Gainers Belite Bio Inc. ADR (NASDAQ: BLTE) shares surged 144.8% to $14.69. Belite Bio priced its 6 million ADS IPO at $6 per ADS.

Get all your
news in one place.

100’s of premium titles.
One news app.

The Guardian - UK

AstraZeneca boss calls for UK to provide new Covid-19 medicine to the vulnerable

Pharmaceutical CEO says it’s ‘sad’ that UK has failed to order Evusheld for the immunosuppressed

Benzinga

The Daily Biotech Pulse: FDA Approves Bristol Myers' Oral Heart Disease Drug, European Approval For Merck's Keytruda, Genocea Restructures, Zymeworks' Takeover Bid

Here's a roundup of top developments in the biotech space over the last 24 hours.

Benzinga

AstraZeneca: Q1 Earnings Insights

AstraZeneca (NASDAQ:AZN) reported its Q1 earnings results on Friday, April 29, 2022 at 08:00 AM. Here's what investors need to know about the announcement. Earnings AstraZeneca reported an EPS of $1.89.

Evening Standard

AstraZeneca faces revenue hit as Covid-19 vaccine demand falls

Pharmaceutical giant has also announced plans to open a new research and development centre in Boston, Massachusetts

Benzinga

AstraZeneca Clocks Q1 COVID Vaccine Sales Of $1.2B, Keeps Overall FY22 Outlook

AstraZeneca Plc's (NASDAQ:AZN) total revenue jumped 60% Y/Y at CER to $11.39 billion in Q1 FY22, beating the consensus of $10.99 billion. The growth reflects the contribution of the Alexion medicines and several Vaxzevria contracts that are expected to complete the delivery by half year 2022. Core EPS came in at $1.89,…

The Independent UK

Sales of Covid vaccine set to decline as demand wanes, AstraZeneca predicts

The business has already seen a significant drop in the use of its vaccines to Europe.

Benzinga

How To Attend AstraZeneca Q1 2022 Earnings Conference Call

AstraZeneca (NASDAQ:AZN) will host a conference call at 06:45 AM ET on April 29, 2022, to discuss Q1 2022 earnings results. How to Attend AstraZeneca (AZN) Conference Call Follow this link to access the live webcast.

1 … 13 14 15 16

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

World Health Organization

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.